Haruhisa Konishi

Mr. Haruhisa Konishi

Hiroshima University, Hiroshima, Japan
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Placenta
Verified
Journal Article
Closed access
HKHaruhisa Konishi
Haruhisa Konishi
SUSatoshi Urabe
Satoshi Urabe
YTYuko Teraoka
Yuko Teraoka
YMYoshito Morishita
Yoshito Morishita
IKIemasa Koh
Iemasa Koh
YKYoshiki KUDO
Yoshiki KUDO

26 July 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
YTYuko Teraoka
Yuko Teraoka
JSJun Sugimoto
Jun Sugimoto
HKHaruhisa Konishi
Haruhisa Konishi
HMHiroshi Miyoshi
Hiroshi Miyoshi
HFHisako Furusho
Hisako Furusho
YKYoshiki KUDO
Yoshiki KUDO
Preterm birth is one of the most significant obstetric complications. Inflammation reportedly promotes uterine contraction and weakening of the fetal membrane, which induces preterm birth. Previous studies using animal models of lipopolysaccharide-induced acute inflammation have shown that progesterone (P4) promotes uterine quiescence. However, this effect is not fully understood in chronic inflammation. This study aimed to investigate the effects of P4 on uterine contractility and inflammation of the fetal membrane in mice infected with Porphyromonas gingivalis (P.g.), a major periodontal pathogen as a model of preterm birth caused by chronic inflammation. Mice were injected with 1 mg of P4 from day 15.5 to 17.5. P4 prolonged the mean gestation period of P.g mice from 18.3 to 20.4 days, and no reduction in the gestation period was observed. P4 treatment suppressed spontaneous uterine contractility and decreased oxytocin sensitivity. In addition, the expression of inflammatory cytokines in the fetal membrane was significantly reduced. Thus, P4 prevented preterm birth by suppressing enhanced uterine contractility induced by chronic inflammation in this model. This result describes the effects of P4 in a chronic inflammation model, which may lead to a better understanding of the efficacy of P4 in preventing preterm birth in humans.

1 January 2018 in Case Reports in Obstetrics and Gynecology
Verified
Journal Article
Open access
PDF file
HKHaruhisa Konishi
Haruhisa Konishi
IKIemasa Koh
Iemasa Koh
NSNoriyuki Shiroma
Noriyuki Shiroma
YKYukie Kidani
Yukie Kidani
SUSatoshi Urabe
Satoshi Urabe
YKYoshiki Kudo
Yoshiki Kudo
Intravenous leiomyomatosis (IVL) is a rare benign neoplasm. Herein, we describe two cases of IVL at different levels of progression. The tumor in Case 1 was extensive, invading the right atrium after a hysterectomy for a uterine myoma. The tumor temporarily responded to hormonal treatment; however, tumor regrowth occurred. In contrast, the tumor in Case 2 extended only to the pelvic veins and was revealed preoperatively. Hysterectomy and bilateral salpingo‐oophorectomy were performed, resulting in the complete surgical resection of the tumor. In Case 2, no recurrence has been observed. Tumor samples were evaluated for hyaluronan expression using Alcian blue staining (with and without hyaluronidase digestion). The tumor in Case 1 stained strongly positive for hyaluronan while the tumor in Case 2 stained weakly positive for hyaluronan. In contrast, a large non‐IVL uterine leiomyoma (control) stained negative for hyaluronan. These results suggest a relationship between tumor hyaluronan expression and IVL progression, similar to that in other cancers.

1 January 2025 in Reproductive Medicine and Biology
Verified
Journal Article
Open access
HKHaruhisa Konishi
Haruhisa Konishi
YNYoshiharu Nakaoka
Yoshiharu Nakaoka
AMAnmae Michiko
Anmae Michiko
SFSho Fujiwara
Sho Fujiwara
RKRie Kitayama
Rie Kitayama
Yoshiharu MorimotoYoshiharu Morimoto
Yoshiharu Morimoto
Purpose: Preimplantation genetic testing for monogenic disorders ( PGT ‐M) offers BRCA variant carriers the option of preventing hereditary cancer transmission. We investigated the awareness and attitudes toward PGT ‐M among patients with breast cancer who underwent fertility preservation. Methods: A questionnaire‐based survey was administered to 264 patients with breast cancer who were eligible for oocyte or embryo cryopreservation at in vitro fertilization clinics between October 2024 and March 2025. A total of 161 valid responses were analyzed. The survey assessed BRCA testing status, PGT ‐M awareness, willingness to undergo PGT ‐M, and opinions on future availability. Results: The uptake rate of BRCA1 /2 testing was 53.4%; 14% of the respondents were variant carriers. Only 16.8% had prior awareness of PGT ‐M, and 47.8% expressed a willingness to use PGT ‐M if available. Among BRCA ‐variant carriers, 3.3% reported that they would consider PGT ‐M, and 75% believed it should be made available upon request. Overall, 68.3% supported information sharing between oncology and fertility providers. Conclusion: These findings highlight the importance of expanding reproductive options and patient awareness of PGT ‐M in the care of patients with hereditary cancer. Discussions should focus on how best to provide accurate information and enable informed reproductive choices for those at genetic risk.

7 March 2026 in Middle East Fertility Society Journal
Verified
Journal Article
Open access
PDF file
HKHaruhisa Konishi
Haruhisa Konishi
HMHiroshi Matsumoto
Hiroshi Matsumoto
SFSho Fujiwara
Sho Fujiwara
RKRie Kitayama
Rie Kitayama
DKDaisuke Kadogami
Daisuke Kadogami
YMYoshiharu Morimoto
Yoshiharu Morimoto
Background: Optimal endometrial preparation for frozen-thawed embryo transfer (FET) remains debated owing to conflicting results regarding outcomes in modified natural ovulation cycles (NCs) versus hormone replacement cycles (HRCs). Therefore, we aimed to compare clinical pregnancy and miscarriage rates between modified NCs and HRCs in FETs. We retrospectively analyzed 9,136 clinical pregnancies by FET between January 2020 and February 2025 at three IVF JAPAN GROUP fertility clinics. Of these, 5,230 were HRCs and 3.906 were modified NCs. Clinical pregnancy was defined as the presence of a gestational sac, while miscarriage was defined as pregnancy loss before 9 weeks of gestation. Subgroup and multivariate analyses were performed, adjusting for maternal age, prior miscarriage, embryo developmental stage, and use of preimplantation genetic testing for aneuploidy. Results: Miscarriage rates were lower in the modified NC group compared with the HRC group (19.4% vs. 25.6%; P < 0.001). This reduction was also observed in high-risk subgroups, including women aged ≥ 40 and those with prior miscarriage. Multivariate analysis confirmed the association (adjusted odds ratio: 0.74; 95% confidence interval: 0.66–0.82). This trend was consistent across all facilities, despite differing NC utilization rates, and was independent of chromosomal status. Conclusions: Given that HRC remains the dominant strategy in many countries, our findings indicate that modified NC in FET may provide clinical benefits in early pregnancy outcomes.